Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Tuesday. AECOM Technology Corporation (NYSE: ACM) Cut to Underperform at BofA/ML. Alnylam Pharmaceuticals,…
The major US stock indexes opened lower this morning following a weekend of elections in Europe. A new Socialist party president in France and a still very cloudy future in Greece have…
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is trading up so much higher that you might think the company is being acquired. The real reason for the huge share gains is based upon results…
Jon C. Ogg Jon OggThese are some of today’s top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Tuesday. Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) Started as Outperform with $11 target at Credit…
News from Abbott Laboratories (NYSE: ABT) on its positive Phase II study results from two different interferon-free hepatitis C treatment has the entire drug sector up in arms as it pertains to…
Gilead Sciences, Inc. (NASDAQ: GILD) has recovered from its pre-market lows on the devastating news that its Hepatitis C drug experienced close to a total failure in an arm of a late-stage…
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is trading lower after earnings, but this may be due more to a give back from big gains this week and it may be a headline issue. The…
Jon C. Ogg Earnings season is still upon us. There are going to be many big earnings reports Thursday and we would consider Thursday as the climax for the companies reporting their normal fourth quarter…
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms this Wednesday morning. Amazon.com Inc. (NASDAQ: AMZN) Maintained Neutral but cut target…
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has announced another FDA approval. While this approval will treat cystic fibrosis, the current total patient population is rather small if the numbers are not meant to…
Jon C. Ogg Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) has been on fire due to the rapid interest of hepatitis C treatments and the bidding of players in the sector. With Merck & Co. (NYSE: MRK) driving further…
You know how stocks sometimes react to news on peers… Today we are again seeing a run in the world of Hepatitis C drug candidates after news that Bristol-Myers Squibb Co. (NYSE: BMY)…
For several years it has been the case that Amgen Inc. (NASDAQ: AMGN) was considered a biotech though it had at least some of the same problems of Big Pharma players like Pfizer Inc.…
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Wednesday morning. Altria Group Inc. (NYSE: MO) Cut to Hold at Stifel Nicolaus.…
The deal between Gilead and Phamasset is driving other hepatitis C developers higher this morning. Whether the 90% or so premium is a true read on just how bad this is up to…
Jon C. Ogg 
